SCHEMBL1124428

SCHEMBL1124428

COC(=O)[C@H](Cc1ccccc1)N(Cc1ccc(-c2ccccn2)cc1)C(=O)/C=C/c1ccc(C(F)(F)F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 5/20 0.51
NOS1 P29475 5/20 0.51
NOS2 P35228 5/20 0.51
TRPM8 Q7Z2W7 1/20 0.43
UGT1A1 P22309 2/20 0.42
MLNR O43193 1/20 0.42
NR1I2 O75469 1/20 0.42
SLCO2B1 O94956 1/20 0.42
ABCB11 O95342 1/20 0.42
ABCB1 P08183 1/20 0.42
CCKAR P32238 1/20 0.42
OPRK1 P41145 1/20 0.42
GHSR Q92847 1/20 0.42
SLCO1B3 Q9NPD5 1/20 0.42
ABCG2 Q9UNQ0 1/20 0.42
SLCO1B1 Q9Y6L6 1/20 0.42
HTR5A P47898 3/20 0.41
TRPV1 Q8NER1 1/20 0.41
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1124430 1.00 NOS3 (0.51) NOS3NOS1NOS2TRPM8UGT1A1
SCHEMBL1124433 1.00 NOS3 (0.51) NOS3NOS1NOS2TRPM8UGT1A1
SCHEMBL2375592 0.92 NOS3 (0.44) NOS3NOS1NOS2TRPM8HTR5A
SCHEMBL2375587 0.92 NOS3 (0.44) NOS3NOS1NOS2TRPM8HTR5A
SCHEMBL2375583 0.92 NOS3 (0.44) NOS3NOS1NOS2TRPM8HTR5A
SCHEMBL2374579 0.91 NOS3 (0.43) NOS3NOS1NOS2TRPM8HTR5A
SCHEMBL2374585 0.91 NOS3 (0.43) NOS3NOS1NOS2TRPM8HTR5A
SCHEMBL2374575 0.91 NOS3 (0.43) NOS3NOS1NOS2TRPM8HTR5A
SCHEMBL1124512 0.91 TRPV1 (0.42) NOS3NOS1NOS2TRPM8UGT1A1
SCHEMBL1124509 0.91 TRPV1 (0.42) NOS3NOS1NOS2TRPM8UGT1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281869-A1 TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS AISSAOUI HAMED (FR) 2011-11-17 US disclosed
US-20110281869-A1 TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS AISSAOUI HAMED (FR) 2011-11-17 US disclosed
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US disclosed
EP-2282996-A1 TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS Actelion Pharmaceuticals Ltd. (CH) 2011-02-16 EP disclosed
WO-2009141782-A1 TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS ACTELION PHARMACEUTICALS LTD (CH) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS CTSA, BECN1, HDAC6 NOS3 783/4885NOS1 996/4885NOS2 548/4885
US-20110281869-A1 TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS QTRT2, RECQL, QTRT1 NOS3 1013/4885NOS1 1977/4885NOS2 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.